Bio-Rad (BIO) Laboratories “announced that the company has entered into a binding offer to purchase all equity interests in Stilla Technologies. The acquisition remains subject to consultation with relevant employee representatives, regulatory approvals, and other customary closing conditions, and is expected to close by the end of the third quarter of 2025. With operations in France and the U.S., Stilla develops and markets next-generation digital PCR instruments, consumables, and assays. The company’s Nio(R) family of all-in-one digital PCR systems aids the development of a wide range of genetic tests and molecular assays across multiple applications including liquid biopsy for oncology diagnostics, cell and gene therapy, organ transplant testing, infectious diseases, and food and environmental testing.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIO:
Questions or Comments about the article? Write to editor@tipranks.com